The first, controlled clinical trial of Pervistop™ included 40 female patients with persistent HPV infections and low-grade cervical lesions (LSIL).

20 of the patients were treated with Pervistop™, 1 tablet per day for 3 months while 20 were left untreated (control group).

After the 3 months, the following was shown in the Pervistop™ group**:

• LSIL regression in 85% of treated patients
• 85% of women had a negative HPV-DNA test
• Most people experienced no or minor side effects (gastrointestinal disturbances)
• Results were statistically significant (p ≈ 0.0001 vs control group)

**These results must be replicated in a larger clinical trial, with more patients to confirm safety and effectiveness

1. Aragona C et al. (2023). Evaluating the Efficacy of Pervistop®, a New Combination Based on EGCG, Folic Acid, Vitamin B12 and Hyaluronic Acid on Patients with Human Papilloma Virus (HPV) Persistent Infections and Cervical Lesions: A Pilot Study. Journal of clinical medicine, 12(6), 2171.

Recent clinical research has further confirmed the benefits of Pervistop™ in supporting women with persistent HPV infections and cervical lesions.
In a prospective clinical study – published by Porcaro et al., 2025 – 106 women with cervical high-risk HPV infections were enrolled and all received Pervistop™ (1 tablet/day for 6 months).

After 6 months of supplementation, the study reported:

• Viral clearance in 85.8% of enrolled patients;
• Complete regression of HPV-induced cervical lesions in 92.3% of cases;
• 71.8% of patients with persistent infection tested negative to HPV DNA;
• No reported adverse effects.

Porcaro G et al. Oral Treatment with EGCG, Folic Acid, Vitamin B12, and Hyaluronic Acid Improves HPV Clearance and Counteracts Its Persistence: A Clinical Study. Int J Mol Sci. 2025 May 29;26(11):5251.

In a controlled open label clinical trial conducted within the regional HPV screening program in Puglia (Italy), 163 women with HPV infection were enrolled; 86 received Pervistop (once daily for 3 months), while 77 followed standard clinical surveillance. 

After 3 months (T1) 

• In the treatment group, the percentage of women who still had HPV on the DNA test dropped from 47.6% at the start to 18.6%. In the control group, it went from 58.4% to 40.3%, so the reduction was clearly greater with the supplement.
• 40.7% of treated women had a normal Pap test after 3 months, compared with only 9.1% in the control group.

• In the treatment group, 83.7% of women had a normal Pap test by 6 months, and none developed high-grade lesions.
• In the control group, only 36.4% had a normal Pap test and 6.5% of women developed high-grade lesions (HSIL)

Adverse events were not described in the publication.

Tinelli A et al. Treatment with Epigallocatechin Gallate, Folic Acid, Vitamin B12, and Hyaluronic Acid Decreases HPV Positivity in Women Attending Regional Screening in Puglia. Microorganisms. 2024 Sep 14;12(9):1897.

An “in-vitro study” is when scientists do experiments and tests on cells or tiny parts of the body in a lab dish, instead of inside a living person or animal.

SUMMARY**:

• The human papilloma virus (HPV) is responsible for most cases of cervical cancer worldwide.
• While many HPV infections go away on their own and pre-cancerous lesions can heal, some infections persist and might lead to more serious cervical cancer.
• The study aimed to see what happens when a combination of substances (EGCG, FA, B12, and HA) is used on HPV-positive cervical cancer cells (HeLa cells).
• The combination of these substances caused a notable increase in cell death (apoptosis) and in the activity of the p53 gene, decreased.
• This research suggests that the combination of EGCG, FA, B12, and HA might have a beneficial effect against HPV infection by increasing cell death and p53 gene activity in HPV-infected cervical cells (HeLa cells).

**NOTE: Because this study was done on cells in a lab, and not on humans, one cannot relate the results to how the product would work in humans. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

2. Frega A et al. (2023). Epigallocatechin gallate, folic acid, vitamin B12, and hyaluronic acid significantly increase apoptosis and p53 expression in HeLa cells. European review for medical and pharmacological sciences, 27(11), 5240–5245.

SUMMARY:

• Human papillomavirus (HPV) infections are commonly sexually transmitted worldwide.
• More than 90% of HPV infections are asymptomatic, transient, and regress within 6-12 monhs, but in some cases, the infection can persist over a year, increasing the probability of developing malignant tumors.
• HPV vaccines may reduce, but not eliminate, the risk of cervical cancer without altering the course of existing HPV infections.
• Scientific researches has highlighted the potential role of some natural supplements in preventing persistent HPV infections and/or promoting the regression of HPV-related lesions, with a special focus on epigallocatechin gallate (EGCG), folic acid, vitamin B12 and hyaluronic acid (HA).
• EGCG (from green tea) can inhibit the proliferation of HPV-infected cells by interfering with the viral life cycle, promoting degradation of the E6 and E7 oncoproteins. 
• Folate and vitamin B12: low levels are linked to HPV infection, so supplementing these vitamins may help limit HPV genome integration and promote viral clearance.
• Hyaluronic Acid can help prevent HPV infection by supporting tissue healing, acts as an important adjuvant that enhances the effect of other compounds and may reduce lesion burden.

Laganà AS, Chiantera V, Gerli S, Proietti S, Lepore E, Unfer V, Carugno J, Favilli A. Preventing Persistence of HPV infection with Natural Molecules. Pathogens. 2023 Mar 6;12(3):416.

The comparative review by Porcaro et al., 2025 evaluates available supplement formulations proposed in HPV care, focusing on combination of epigallocatechin Gallate (EGCG), Folic Acid (FA), Vitamin B12 (B12), and Hyaluronic Acid (HA). The review analyzes clinical studies on multiple HPV-targeted formulations.

Key findings:

• The oral combination of EGCG, FA, B12, and HA is supported by multiple clinical investigations (case reports, controlled clinical trials, an open-lable controlled study in a regional screening setting, and a single-arm open-label trial), which consistently report high rates of HPV clearance and regression of low-grade cervical lesions over 3-6 months of treatment.
• In studies on the EGCG, FA, B12, and HA combination patient adherence was complete in three trials, while tolerability was favorable, with no adverse effects reported by Porcaro et al., and only one gastrointestinl event, promptly resolved without treatment discontinuation, described by Aragona et al.
• Among the different strategies assessed in the study, the combination of EGCG, FA, B12, and HA demonstrated more solid and promising results in terms of HPV clearance and regression of lesions, with statistically significant effects observed as early as three months.

Porcaro G et al. Medicinal Mushrooms, Probiotics and Combination of Natural Compounds in the Management of HPV: A Comparative Look at Viral Clearance and Lesion Resolution. Viruses. 2025 Jul 2;17(7):942.

One recent clinical evidence on Pervistop™ includes a case series of five women with long-term persistent HPV infections (from 1 to 7 years), affecting both cervical and anal areas.
Each patient received Pervistop™ for 3 to 6 months, depending on clinical history.

After treatment, the following was observed:

• 100% of patients test negative HPV-DNA
• Cytological lesions and inflammation significantly improved
• Both cervical and anal HPV infections responded positively to treatment
• Adverse events were not described in the publication. 

These results support the potential of Pervistop™ as an approach to counteract HPV persistence, although further clinical studies with larger populations and longer follow-up are required to confirm safety and efficacy.

Calcagno M et al. Counteracting HPV Cervical and Anal Infection through Dietary Supplementation of EGCG, Folic Acid, Vitamin B12 and Hyaluronic Acid: Clinical Case Reports. J Clin Med. 2024 Jun 19;13(12):3597.

One recent clinical report on Pervistop™ describes a 39-year-old woman with a 9-year history of persistent HPV-16 infection with recurrent high-grade cervical lesions (up to HSIL/CIN3) despite three LEEPs and one laser conization. Due to this condition, she received a medical indication for hysterectomy. As it is an irreversible procedure and considering the fertile age of the patient, she decided to ask for another medical opinion, becoming the subject of this case report study.

She started oral supplementation with Pervistop for 8 weeks, taking 2 tablets per day :

• After treatment, Pap test and cervical biopsy showed only chronic cervicitis, with no intraepithelial or malignant lesions.
• At 6-month follow-up, colposcopy, Pap test and HPV-DNA test were all negative.

This favorable clinical course allowed the patient to avoid the hysterectomy that had been proposed as the only therapeutic option.

Grandi G, Botticelli L, Di Fraia P, Babalini C, Masini M, Unfer V. The Association of Four Natural Molecules – EGCG, Folic Acid, Vitamin B12 and HA – To Counteract HPV Cervical Lesions: A Case Report. Journal of Personalized Medicine. 2023;13(3):567.